Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Fig. 2

Normalized CCND1 levels in patient peripheral blood samples. CCND1 mRNA was assessed using ddPCR on RNA extracted from PBMCs as described in the “Methods” section. Positive controls were the MCL cell line JVM2, and PBMCs from untreated patient with MCL involvement. Negative control was PBMCs from a healthy donor. Shown are results of single samples from patients A1-A18

Back to article page